Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 45.32
2
Healthy long term growth as Operating profit has grown by an annual rate 29.93%
3
Negative results in Jun 25
4
With ROE of 13.85%, it has a very attractive valuation with a 1.62 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 4,021 Million (Micro Cap)
12.00
NA
0.00%
0.10
14.41%
1.50
Revenue and Profits:
Net Sales:
1,991 Million
(Quarterly Results - Jun 2025)
Net Profit:
81 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.87%
0%
-14.87%
6 Months
-11.69%
0%
-11.69%
1 Year
-1.14%
0%
-1.14%
2 Years
-5.44%
0%
-5.44%
3 Years
-5.62%
0%
-5.62%
4 Years
-1.51%
0%
-1.51%
5 Years
30.9%
0%
30.9%
Sincere Co., Ltd. (Japan) for the last several years.
Risk Adjusted Returns v/s 
News

Sincere Co., Ltd. Adjusts Evaluation Amid Mixed Financial and Technical Indicators
Sincere Co., Ltd. has recently transitioned from an unassigned status to a Hold evaluation, reflecting a cautious market outlook. While technical indicators show mixed signals, the company maintains strong debt management and healthy long-term growth, presenting a complex picture of stability and potential challenges.
Read More Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.03%
EBIT Growth (5y)
29.93%
EBIT to Interest (avg)
45.32
Debt to EBITDA (avg)
0.60
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
1.40
Tax Ratio
32.77%
Dividend Payout Ratio
40.22%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.92%
ROE (avg)
8.80%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.62
EV to EBIT
8.12
EV to EBITDA
6.96
EV to Capital Employed
1.53
EV to Sales
0.70
PEG Ratio
0.18
Dividend Yield
NA
ROCE (Latest)
18.86%
ROE (Latest)
13.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,991.40
1,560.10
27.65%
Operating Profit (PBDIT) excl Other Income
143.50
185.50
-22.64%
Interest
6.00
5.50
9.09%
Exceptional Items
-6.70
-6.00
-11.67%
Consolidate Net Profit
81.40
88.40
-7.92%
Operating Profit Margin (Excl OI)
61.70%
98.10%
-3.64%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 27.65% vs -7.89% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -7.92% vs 6.51% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
6,539.40
5,961.50
9.69%
Operating Profit (PBDIT) excl Other Income
564.60
391.50
44.21%
Interest
16.90
8.90
89.89%
Exceptional Items
2.80
74.00
-96.22%
Consolidate Net Profit
309.10
295.50
4.60%
Operating Profit Margin (Excl OI)
74.10%
63.20%
1.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 9.69% vs 6.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 4.60% vs 347.05% in Dec 2023
About Sincere Co., Ltd. (Japan) 
Sincere Co., Ltd. (Japan)
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






